Roth Capital Upgrades Journey Medical (NASDAQ:DERM) to “Strong-Buy”

Roth Capital upgraded shares of Journey Medical (NASDAQ:DERM) to a strong-buy rating in a report published on Friday morning, Zacks.com reports.

Separately, Roth Mkm started coverage on Journey Medical in a report on Friday. They issued a buy rating and a $11.00 price objective for the company.

Journey Medical Price Performance

Shares of NASDAQ:DERM opened at $5.37 on Friday. Journey Medical has a 1-year low of $1.60 and a 1-year high of $8.11. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.21 and a quick ratio of 0.94. The firm’s fifty day moving average is $4.24. The company has a market capitalization of $107.45 million, a P/E ratio of -17.32 and a beta of 0.92.

Journey Medical (NASDAQ:DERM) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.27). Journey Medical had a negative net margin of 5.20% and a negative return on equity of 32.83%. The company had revenue of $13.03 million for the quarter, compared to the consensus estimate of $14.91 million. On average, sell-side analysts anticipate that Journey Medical will post -1.02 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Journey Medical

Large investors have recently bought and sold shares of the business. Nwam LLC bought a new stake in Journey Medical in the 1st quarter worth about $41,000. Heron Bay Capital Management bought a new stake in Journey Medical in the 1st quarter worth about $124,000. Finally, Acadian Asset Management LLC increased its holdings in Journey Medical by 687.5% in the 1st quarter. Acadian Asset Management LLC now owns 222,663 shares of the company’s stock worth $817,000 after buying an additional 194,389 shares in the last quarter. 7.25% of the stock is currently owned by institutional investors.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.